Inflammation and neurological adverse drugs reactions: a case of long lasting impaired consciousness after oxatomide administration in a patient with gastroenteritis

Ital J Pediatr. 2012 Mar 30;38(1):11. doi: 10.1186/1824-7288-38-11.

Abstract

Oxatomide at therapeutic doses generates occasionally drowsiness in children. When administered at toxic doses, however oxatomide may induce long lasting impaired consciousness. We now report a case of severe long lasting impaired consciousness induced by therapeutic doses of oxatomide occurring in a child affected by acute gastroenteritis. The clinical symptoms, the pharmacogenetic tests of polymorphisms in cytochrome P450 metabolizing enzymes (CYPs) and the clinical and laboratory analyses indicate that the enhanced drug sedative effect is likely due to an acute, yet mild, inflammatory state of the patient. These findings highlight the importance of assessing common, not serious inflammatory states when oxatomide is prescribed in paediatric patients.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Allergic Agents / adverse effects*
  • Anti-Allergic Agents / therapeutic use
  • Child, Preschool
  • Conjunctivitis / complications
  • Conjunctivitis / diagnosis
  • Conjunctivitis / drug therapy*
  • Consciousness Disorders / chemically induced*
  • Consciousness Disorders / physiopathology
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Dystonia / chemically induced
  • Dystonia / physiopathology
  • Follow-Up Studies
  • Gastroenteritis / complications
  • Gastroenteritis / diagnosis*
  • Gastroenteritis / drug therapy
  • Humans
  • Male
  • Neurologic Examination
  • Piperazines / adverse effects*
  • Piperazines / therapeutic use
  • Risk Assessment
  • Severity of Illness Index
  • Time Factors

Substances

  • Anti-Allergic Agents
  • Piperazines
  • oxatomide